Back to Browse Journals » ClinicoEconomics and Outcomes Research » Volume 4

Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents

Authors Tarride JE, Burke N, Von Keyserlingk C, O'Reilly D, Xie F, Goeree R

Published Date October 2012 Volume 2012:4 Pages 287—298


Received 1 May 2012, Accepted 21 June 2012, Published 4 October 2012

Jean-Eric Tarride,1,2 Natasha Burke,1,2 Camilla Von Keyserlingk,1,2 Daria O'Reilly,1,2 Feng Xie,1,2 Ron Goeree1,2

1Programs for Assessment of Technology in Health (PATH) Research Institute, St Joseph's Healthcare Hamilton, Hamilton, 2Department of Clinical Epidemiology and Biostatistics, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada

Background: Influenza affects all age groups and is common in children. Between 15% and 42% of preschool- and school-aged children experience influenza each season. Recently, intranasal live attenuated influenza vaccine, trivalent (LAIV) has been approved in Canada.
Objective: The objective of this study was to determine the cost-effectiveness of LAIV compared with that of the injectable inactivated influenza vaccine, trivalent (TIV) in Canadian children and adolescents from both a payer (eg. Ministry of Health) perspective and a societal perspective.
Methods: A cost-effectiveness model comparing LAIV and TIV in children aged 24–59 months old was supplemented by primary (ie, a survey of 144 Canadian physicians) and secondary (eg, literature) data to model children aged 2–17 years old. Parameter uncertainty was addressed through univariate and probability analyses.
Results: Although LAIV increased vaccination costs when compared to TIV, LAIV reduced the number of influenza cases and lowered the number of hospitalizations, emergency room visits, outpatient visits, and parents’ days lost from work. The estimated offsets in direct and societal costs saved were CAD$4.20 and CAD$35.34, respectively, per vaccinated child aged 2–17 years old. When costs and outcomes were considered, LAIV when compared to TIV, was the dominant strategy. At a willingness to pay of CAD$50,000 per quality adjusted life year gained, or CAD$100,000 per quality adjusted life year gained, the probabilistic results indicated that the probability of LAIV being cost-effective was almost 1.
Conclusions: LAIV reduces the burden of influenza in children and adolescents. Consistent with previously reported results, vaccinating children with LAIV, rather than TIV, is the dominant strategy from both a societal perspective and a Ministry of Health perspective.

Keywords: influenza, vaccine, children, cost-effectiveness

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Other article by this author:

Health status, hospitalizations, day procedures, and physician costs associated with body mass index (BMI) levels in Ontario, Canada

Tarride JE, Haq M, Taylor VH, Sharma AM, Nakhai-Pour HR,  O'Reilly D, Xie F, Dolovich L, Goeree R

ClinicoEconomics and Outcomes Research 2012, 4:21-30

Published Date: 24 January 2012

Readers of this article also read:

Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for Italy

Schwander B, Ravera S, Giuliani G, Nuijten M, Walzer S

ClinicoEconomics and Outcomes Research 2012, 4:237-243

Published Date: 3 September 2012

Studying the effect of particle size and coating type on the blood kinetics of superparamagnetic iron oxide nanoparticles

Roohi F, Lohrke J, Ide A, Schuetz G, Dassler K

International Journal of Nanomedicine 2012, 7:4447-4458

Published Date: 10 August 2012

Drug use and self-medication among children with respiratory illness or diarrhea in a rural district in Vietnam: a qualitative study

Le TH, Ottosson E, Nguyen TKC, Kim BG, Allebeck P

Journal of Multidisciplinary Healthcare 2011, 4:329-336

Published Date: 13 September 2011

Describing the hexapeptide identity platform between the influenza A H5N1 and Homo sapiens proteomes

Darja Kanduc

Biologics: Targets and Therapy 2010, 4:245-261

Published Date: 9 September 2010

Two resource distribution strategies for dynamic mitigation of influenza pandemics

Andrés Uribe-Sánchez, Alex Savachkin

Journal of Multidisciplinary Healthcare 2010, 3:65-77

Published Date: 7 July 2010

Use of electronic medical records in oncology outcomes research

Gena Kanas, Libby Morimoto, Fionna Mowat, et al

ClinicoEconomics and Outcomes Research 2010, 2:1-14

Published Date: 24 February 2010

Economic considerations for bariatric surgery and morbid obesity

Eldo E Frezza, Mitchell Wacthell, Bradley Ewing

ClinicoEconomics and Outcomes Research 2009, 1:79-83

Published Date: 10 December 2009

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009

Gene silencing in the therapy of influenza and other respiratory diseases: Targeting to RNase P by use of External Guide Sequences (EGS)

David H Dreyfus, S Mark Tompkins, Ramsay Fuleihan, Lucy Y Ghoda

Biologics: Targets and Therapy 2007, 1:425-432

Published Date: 22 January 2007

Cost-benefit analysis of influenza vaccination in a public healthcare unit

Giorgio L Colombo, Antonio Ferro, Marta Vinci, Maria Zordan, Giulio Serra

Therapeutics and Clinical Risk Management 2006, 2:219-226

Published Date: 20 January 2006